The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | IL-2 mutein-mediated improvement of CAR-T function in R/R DLBCL
Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses preclinical work using an engineered IL-2 mutein to selectively enhance CAR T-cell function while minimizing toxicity, with the goal of reducing exhaustion and improving efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Similar to this idea of like how macrophages could be suppressing CAR T-cell function, what are strategies to kind of prevent that, to boost the T-cell function? So one idea we have is to target macrophages. The other idea we have is can we give the CAR T-cells an extra boost? And we want to use a cytokine, IL-2, for that. So the main problem with IL-2 is a cytokine, when you give it to patients, it can lead to lots of toxicity...
Similar to this idea of like how macrophages could be suppressing CAR T-cell function, what are strategies to kind of prevent that, to boost the T-cell function? So one idea we have is to target macrophages. The other idea we have is can we give the CAR T-cells an extra boost? And we want to use a cytokine, IL-2, for that. So the main problem with IL-2 is a cytokine, when you give it to patients, it can lead to lots of toxicity. Fevers, hypertension, cardiovascular dysfunction. So we’re using a novel IL-2 protein that has been mutated so it does not bind to portions of the high affinity receptor for IL-2, which will bind to Tregs and lead to kind of suppression of CAR T cells. So instead, this mutant specifically binds to the cytotoxic T cells, the ones that are doing the cancer killing. So we’ve set up animal models to show that this IL-2 mutant can support CAR T cell function that can make it resistant to exhaustion. And we’re presenting that at this meeting. And hopefully, we’re also in the process of getting an IND for that IL-2 mutant to be able to do clinical trials with it.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
